This is the authors' abstract. We don't add key points for this paper.
BACKGROUND Early stage constitutes around 40 % of all oral cavity squamous cell carcinoma (OSCC). While the role of adjuvant therapy in advanced cases is well established, its role in early-stage disease remains controversial and is institutional based. Despite treatment advances, the 5-year Disease Free Survival (DFS) falls short of 80 %. METHODS An ambispective observational study was conducted on all early stage (pT1-2, N0) OSCC who underwent curative surgery of the primary and neck from 2019 to 2024 at a tertiary oncology care centre. Patients with a history of radiation, recurrence, neoadjuvant chemotherapy or positive margins were excluded. Primary outcomes were overall survival (OS) and disease-free survival (DFS). Secondary outcomes were factors associated with recurrence, radiation-induced toxicity, and quality of life. RESULTS 1260 OSCC were operated during the study period. 357(28 %) were early stage, and 274 were eligible for analysis. 52(18.9 %) patients had recurrence. 3-year-OS was 92 % and 3-year-DFS was 74 %. Tongue subsite (p = 0.034), depth of invasion (DOI) > 5 mm (p = 0.012), and peri-neural Invasion (PNI) (p = 0.036) were significant predictors of recurrence on multi-variate analysis. On matched-pair analysis patients who received adjuvant radiotherapy had lower rates of recurrence (16.9 % vs 24.6 %, p = 0.2815). Odds of recurrence increased from low to intermediate to high Brandwein-Gensler score (OR - 0.54 vs 0.89 vs 1.54, p = 0.4332). CONCLUSION Tongue/FOM subsite, DOI > 5 mm, and PNI are aggressive features in early-stage OSCC. Adjuvant therapy can help to achieve improved disease control. There is a pressing need to establish definitive indications for adjuvant therapy in pT1-2, N0 OSCC.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Sood et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: